Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leukapheresis (White blood cell removal via filtration) (Leukapheresis or Leukocytapheresis)
- Target
- Leukapheresis or Leukocytapheresis
- Molecular classification
- Other (Therapeutic procedure; NOT a molecule)
01
Overview
Leukapheresis is a medical procedure in which blood is withdrawn, processed through a specialized machine utilizing filtration or centrifugation, and leukocytes are selectively removed from circulation. The remainder of the blood (red cells, plasma, platelets) is reinfused back into the patient. This intervention is used for immediate cytoreduction in patients with critically high white blood cell counts, particularly leukemias, where rapid control is required to prevent complications such as leukostasis, microvascular occlusion, and organ dysfunction. Leukapheresis is adjunct to curative therapies such as chemotherapy or targeted cancer therapies but does not itself eradicate underlying disease. Filtration of white blood cells is also integrated into blood banking (leukoreduction) to reduce transfusion-transmittable diseases and immune complications.
- Other names
- leukocytapheresiscytoreductive apheresiswhite blood cell apheresiswhite blood cell removal
02
Mechanism of action
Physical separation and filtration of leukocytes from blood via apheresis
03
Biological functions
Removal of white blood cells from circulationCytoreductionPreparation for stem cell collection
04
Disease associations
Leukemia (acute and chronic forms)LymphomaAutoimmune disorders with elevated leukocyte countsPrevention and management of leukostasis
05
Safety considerations
Transient low blood volumeCitrate toxicity (hypocalcemia)Numbness, tingling, muscle spasmsInfection, catheter-related complicationsThrombocytopenia or anemia if excessive blood components are removed
06
Interacting drugs
none (not a molecular target, but procedure may be adjunct to chemotherapy, monoclonal antibodies, etc.)
07
Biomarkers
Extremely high white blood cell count (e.g., above specific thresholds)clinical signs of leukostasis
Beyond the preview
Go deeper on Leukapheresis (White blood cell removal via filtration) (Leukapheresis or Leukocytapheresis).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leukapheresis (White blood cell removal via filtration) (Leukapheresis or Leukocytapheresis).